CELC — Celcuity Inc.
$65.25-0.49%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for CELC in the TickerWise workspace.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 87
- Website: https://www.celcuity.com
Latest SEC filings for CELC
Latest CELC news
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 Read article
- Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026 Read article
- Celcuity Appoints David Gryska To Its Board Of Directors Read article
- Why Celcuity Stock Was a Winner on Wednesday Read article
- Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.